Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Clinical Success Rate
    100.0%

    Based on 2 completed trials

    Completion Rate
    100%(2/2)
    Active Trials
    1(33%)
    Results Posted
    100%(2 trials)

    Phase Distribution

    Phase 3
    2
    67%
    Phase 2
    1
    33%

    Phase Distribution

    0

    Early Stage

    1

    Mid Stage

    2

    Late Stage

    Phase Distribution3 total trials
    Phase 2Efficacy & side effects
    1(33.3%)
    Phase 3Large-scale testing
    2(66.7%)

    Highest Phase Reached

    Phase 3

    Trial Status & Enrollment

    Completion Rate

    100.0%

    2 of 2 finished

    Non-Completion Rate

    0.0%

    0 ended early

    Currently Active

    1

    trials recruiting

    Total Trials

    3

    all time

    Status Distribution
    Active(1)
    Completed(2)

    Detailed Status

    Completed2
    Active, not recruiting1

    Development Timeline

    Analytics

    Development Status

    Total Trials
    3
    Active
    1
    Success Rate
    100.0%
    Most Advanced
    Phase 3

    Trials by Phase

    Phase 21 (33.3%)
    Phase 32 (66.7%)

    Trials by Status

    completed267%
    active_not_recruiting133%

    Recent Activity

    1 active trials
    Showing 3 of 3
    active_not_recruitingphase_3

    S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer

    NCT00070564
    completedphase_3

    Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer

    NCT00041119
    completedphase_2

    Doxorubicin and Cyclophosphamide in Treating Older Women With Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery

    NCT00424203

    Clinical Trials (3)

    Showing 3 of 3 trials
    NCT00070564Phase 3

    S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer

    Active Not Recruiting
    NCT00041119Phase 3

    Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer

    Completed
    NCT00424203Phase 2

    Doxorubicin and Cyclophosphamide in Treating Older Women With Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery

    Completed

    All 3 trials loaded

    Drug Details

    Intervention Type
    Drug
    Total Trials
    3